Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Traws Pharma Inc. (NASDAQ: TRAW) reported a significant increase in its stock price, rising 150.4% after announcing successful Phase 1 trial results for its H5N1 bird flu treatment, tivoxavir marboxil. The treatment demonstrated safety and achieved a 23-day protection period against the virus. The company plans to initiate Phase 2 trials in early next year. Additionally, Despegar.com Corp. (NYSE: DESP) saw its shares rise by 32.8% following an agreement by Prosus to acquire the company for $19.50 per share in a $1.7 billion deal expected to close in Q2 2025.
$TRAW reported that its lead candidate, tivoxavir marboxil, a one-dose oral therapy for avian influenza (H5N1), showed potent antiviral activity in preclinical models, reducing viral load and improving survival in mice. See More Biotech Updates👇 https://t.co/KXAiyCAHYC $RAPT… https://t.co/TkXZe6mqzC
Market Recap📈📉 $TRAW: Up 150.4% after its bird flu treatment showed safety in a Phase 1 trial, with Phase 2 set for early next year. $DESP: Up 32.8% after Prosus agreed to buy the platform for $19.50 per share in a $1.7 billion deal closing in Q2 2025. $HMC: Up 12.8%…
$TRAW Another low floater mover earlier today from $5 to $19 (no position) on preclinical news for bird flu Low floaters, if good data, usually followed by big spikes $ENSC a float even more thin, with 52 week high of $30, could see a big spike if company reports +ve data Long…
